DVA vs THC
DaVita Inc. and Tenet Healthcare Corp., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | DVA | THC |
|---|---|---|
| Revenue | $13.6B | $21.3B |
| Net income | $746.8M | $2.4B |
| Gross margin | · | · |
| Net margin | 7.9% | 11.1% |
| Return on equity | · | · |
| Diluted EPS | $9.84 | $15.49 |
| Dividend / share | · | · |
| Payout ratio | 0.0% | · |
| Free cash flow | $1.3B | $2.5B |
| Equity | $-651.1M | $4.2B |
| Net debt / equity | · | 2.42× |
| Current ratio | 1.29× | 1.76× |
| Revenue CAGR 5y | 3.4% | 3.9% |
| Profit CAGR 5y | −0.7% | 25.2% |
THC bills 1.6× the revenue of DVA, and keeps more of each dollar of revenue as profit (11.1% against 7.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | DVA | THC |
|---|---|---|
| FY2025 | $13.6B | $21.3B |
| FY2024 | $12.8B | $20.7B |
| FY2023 | $12.1B | $20.6B |
| FY2022 | $11.6B | $19.2B |
| FY2021 | $11.6B | $19.5B |
| FY2020 | $11.6B | $17.6B |
| FY2019 | $11.4B | $18.5B |
| FY2018 | $11.4B | $18.3B |
| FY2017 | $10.9B | $20.6B |
| FY2016 | $10.7B | $21.1B |
Bottom line
| Fiscal year | DVA | THC |
|---|---|---|
| FY2025 | $746.8M | $2.4B |
| FY2024 | $936.3M | $4.1B |
| FY2023 | $691.5M | $1.3B |
| FY2022 | $560.4M | $1.0B |
| FY2021 | $978.5M | $1.5B |
| FY2020 | $773.6M | $768.0M |
| FY2019 | $811.0M | $171.0M |
| FY2018 | $159.4M | $459.0M |
| FY2017 | $663.6M | $-320.0M |
| FY2016 | $879.9M | $176.0M |
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$7,666,931,000 | THC |
| FY2024 | −$7,859,450,000 | THC |
| FY2023 | −$8,423,853,000 | THC |
| FY2022 | −$7,564,106,000 | THC |
| FY2021 | −$7,866,203,000 | THC |
| FY2020 | −$6,089,396,000 | THC |
| FY2019 | −$7,090,521,000 | THC |
| FY2018 | −$6,908,149,000 | THC |
| FY2017 | −$9,736,366,000 | THC |
| FY2016 | −$10,362,533,000 | THC |
| FY2015 | −$10,128,755,000 | THC |
| FY2014 | −$5,112,894,000 | THC |
| FY2013 | −$294,950,000 | THC |
| FY2012 | −$1,717,720,000 | THC |
| FY2011 | −$1,922,194,000 | THC |
| FY2010 | −$2,045,390,000 | THC |
THC has reported the higher revenue in every one of these 16 fiscal years. The gap has widened since the earliest year compared.
16 of 18 comparable fiscal years — a year missing data on either side is not counted.
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −3.2 pp | THC |
| FY2024 | −9.9 pp | THC |
| FY2023 | +1.5 pp | DVA |
| FY2022 | +1.5 pp | DVA |
| FY2021 | +2.9 pp | DVA |
| FY2020 | +4.3 pp | DVA |
| FY2019 | +8.0 pp | DVA |
| FY2018 | +0.4 pp | DVA |
| FY2017 | +9.2 pp | DVA |
| FY2016 | +8.8 pp | DVA |
| FY2015 | +3.9 pp | DVA |
| FY2014 | +6.3 pp | DVA |
| FY2013 | +7.3 pp | DVA |
| FY2012 | +6.5 pp | DVA |
| FY2011 | +7.4 pp | DVA |
| FY2010 | −6.2 pp | THC |
The higher net margin has changed hands between DVA and THC over this period.
16 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
THC's net margin has been more volatile than DVA's over the 16 comparable fiscal years — 5.7 percentage points of standard deviation against 1.9.
16 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between DVA and THC over these 16 fiscal years — DVA led in 13 and THC in 3.
16 of 18 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
THC's return on equity has been more volatile than DVA's over the 3 comparable fiscal years — 31.2 percentage points of standard deviation against 0.8.
3 of 17 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between DVA and THC over these 3 fiscal years — DVA led in 1 and THC in 2.
3 of 17 comparable fiscal years — a year missing data on either side is not counted.